CLX

Systematic screening reveals The Clorox Company (CLX) presents an unusual balance sheet structure, with negative tangible equity driving a price-to-book ratio of 46.1x alongside an exceptionally high debt-to-equity ratio of 7.86x. This capital structure reflects substantial intangible assets and leverage typical of mature branded consumer goods companies, yet the operational performance demonstrates resilience with a net margin of 11.18% and operating margin of 14.62%.

The model flags several distinctive profitability metrics despite recent headwinds. Return on equity registered at 453.68%, though this figure amplifies due to the negative equity base. More meaningful operational indicators include ROA of 13.07% and ROI of 23.37%, suggesting management continues extracting value from deployed capital. The company's gross margin of 43.85% reflects sustained pricing power in household essentials, while EPS growth of 10.56% year-over-year contrasts sharply with revenue contraction of -3.69%, indicating margin expansion and potential operational efficiency gains.

Research perspectives identify specific risk factors:

• The current ratio of 0.84 signals near-term liquidity constraints that warrant monitoring alongside the elevated leverage profile
• Trading 28% below its 52-week high of $132.03, the stock reflects market concerns about top-line momentum in a normalizing post-pandemic consumption environment
• Beta of 0.53 positions CLX as a defensive holding during volatility periods

Relative to peers including Procter & Gamble (PG), Colgate-Palmive (CL), and Kimberly-Clark (KMB), CLX trades at a P/E of 15.31x and price-to-sales of 1.71x, representing a valuation discount that systematic screens attribute to the combination of revenue pressure and balance sheet leverage.